Spontaneous Bacterial Peritonitis Medication

  • Author: Thomas E Green, DO, MPH, FACOEP, FACEP; Chief Editor: Rick Kulkarni, MD   more...
 
Updated: Dec 7, 2011
 

Medication Summary

The goals of pharmacotherapy in patients with spontaneous bacterial peritonitis (SBP) are to reduce morbidity and prevent complications. Antibiotics are initially chosen empirically, as these patients may die from overwhelming infection if treatment is delayed until culture results become available.[4]

Next

Antimicrobials

Class Summary

Traditionally, a combination of an aminoglycoside and ampicillin was used to treat spontaneous bacterial peritonitis (SBP). This regimen affords excellent empiric coverage of more than 90% of cases of spontaneous bacterial peritonitis caused by gram-negative aerobes or gram-positive cocci.

More recently, the third-generation cephalosporin cefotaxime has been demonstrated to be as efficacious as the ampicillin/aminoglycoside combination, and it does not carry the increased risk of nephrotoxicity in cirrhotic patients. Cefotaxime does not cover enterococci (up to 5% of cases).

Cefotaxime (Claforan)

 

A third-generation cephalosporin with broad gram-negative spectrum, cefotaxime has lower efficacy against gram-positive organisms and higher efficacy against resistant organisms. Thus, it provides excellent empiric coverage of SBP. By binding to 1 or more penicillin-binding proteins, cefotaxime arrests bacterial cell wall synthesis and inhibits bacterial growth.

Gentamicin

 

Gentamicin is an aminoglycoside antibiotic effective against Pseudomonas aeruginosa; E coli; and Proteus, Klebsiella, and Staphylococcus species. Dosing regimens are numerous; adjust dose based on creatinine clearance (CrCl) and changes in volume of distribution. Gentamicin may be given IV or IM.

Ampicillin

 

Ampicillin interferes with bacterial cell wall synthesis during active multiplication, causing bactericidal activity against susceptible organisms.

Norfloxacin (Noroxin)

 

Norfloxacin is used for prophylaxis in the outpatient setting (400 mg/d). It is a fluoroquinolone with activity against pseudomonads, streptococci, MRSA, S epidermidis, and most gram-negative organisms, but it has no activity against anaerobes. It inhibits bacterial DNA synthesis and, consequently, growth.

Ciprofloxacin (Cipro)

 

Ciprofloxacin is used for prophylaxis in the outpatient setting (750 mg weekly). It is a fluoroquinolone that inhibits bacterial DNA synthesis and, consequently, growth, by inhibiting DNA gyrase and topoisomerases, which are required for replication, transcription, and translation of genetic material. Quinolones have broad activity against gram-positive and gram-negative aerobic organisms. This agent has no activity against anaerobes.

Sulfamethoxazole and trimethoprim (Bactrim DS, Septra DS)

 

This agent is used as prophylaxis in the outpatient setting (5 doses of double-strength trimethoprim-sulfamethoxazole per week (Monday through Friday). It inhibits bacterial growth by inhibiting the synthesis of dihydrofolic acid.

Previous
 
Contributor Information and Disclosures
Author

Thomas E Green, DO, MPH, FACOEP, FACEP  Attending Physician, Emergency Department, Franciscan Saint James Hospital; Assistant Professor and Core Faculty, Emergency Medicine Residency, Chicago College of Osteopathic Medicine at Midwestern University

Thomas E Green, DO, MPH, FACOEP, FACEP is a member of the following medical societies: American College of Emergency Physicians, American College of Osteopathic Emergency Physicians, and American Osteopathic Association

Disclosure: Nothing to disclose.

Coauthor(s)

Steven M Bandy, MD, FACEP  Adjunct Clinical Professor of Emergency Medicine, Virginia College of Osteopathic Medicine; Staff Physician, Department of Emergency Medicine, Johnston Memorial Hospital; Medical Director, Rejuvenage Medspa; Operational Medical Director, Virginia Operations, Wings Air Rescue Ambulance Service

Steven M Bandy, MD, FACEP is a member of the following medical societies: American Academy of Cosmetic Surgery, American College of Emergency Physicians, and American Society for Laser Medicine and Surgery

Disclosure: Nothing to disclose.

Chief Editor

Rick Kulkarni, MD  Attending Physician, Department of Emergency Medicine, Cambridge Health Alliance, Division of Emergency Medicine, Harvard Medical School

Rick Kulkarni, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Emergency Medicine, American College of Emergency Physicians, American Medical Association, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine

Disclosure: WebMD Salary Employment

References
  1. Lata J, Stiburek O, Kopacova M. Spontaneous bacterial peritonitis: a severe complication of liver cirrhosis. World J Gastroenterol. Nov 28 2009;15(44):5505-10. [Medline]. [Full Text].

  2. Bert F, Noussair L, Lambert-Zechovsky N, Valla D. Viridans group streptococci: an underestimated cause of spontaneous bacterial peritonitis in cirrhotic patients with ascites. Eur J Gastroenterol Hepatol. Sep 2005;17(9):929-33. [Medline].

  3. Cholongitas E, Papatheodoridis GV, Lahanas A, Xanthaki A, Kontou-Kastellanou C, Archimandritis AJ. Increasing frequency of Gram-positive bacteria in spontaneous bacterial peritonitis. Liver Int. Feb 2005;25(1):57-61. [Medline].

  4. [Guideline] Runyon BA. Management of adult patients with ascites due to cirrhosis: an update. Hepatology. Jun 2009;49(6):2087-107. [Medline].

  5. Riggio O, Angeloni S. Ascitic fluid analysis for diagnosis and monitoring of spontaneous bacterial peritonitis. World J Gastroenterol. Aug 21 2009;15(31):3845-50. [Medline]. [Full Text].

  6. Chinnock B, Gomez R, Hendey GW. Peritoneal fluid cultures rarely alter management in patients with ascites. J Emerg Med. Jan 2011;40(1):21-4. [Medline].

  7. Gaya DR, David B Lyon T, Clarke J, Jamdar S, Inverarity D, Forrest EH, et al. Bedside leucocyte esterase reagent strips with spectrophotometric analysis to rapidly exclude spontaneous bacterial peritonitis: a pilot study. Eur J Gastroenterol Hepatol. Apr 2007;19(4):289-95. [Medline].

  8. Runyon BA. Monomicrobial nonneutrocytic bacterascites: a variant of spontaneous bacterial peritonitis. Hepatology. Oct 1990;12(4 Pt 1):710-5. [Medline].

Previous
Next
 
Gram-negative Escherichia coli.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.